

Piśmiennictwo

Każdą pozycję oznaczono symbolem A-G, które określają charakter pracy:

- A) Badanie kliniczne prospektywne, z doбором losowym badanych, obejmujące leczonych i grupę kontrolną w podwójnie ślepej próbie.
- B) Badanie kliniczne prospektywne, ale nie spełniające kryteriów badania randomizowanego.
- C) Badanie prospektywne określonej grupy chorych lub przebiegu, w którym nie planowano określonych interwencji.
- D) Badanie kontrolowane. Ocena retrospektywna grupy chorych i grupy kontrolnej.
- E) Wtórna analiza dostępnych danych, np. decyzyjna lub metaanaliza.
- F) Praca pogładowa porównująca dane (jakościowe) opublikowane.
- G) Inne – dane podręcznikowe, opinie ekspertów, doniesienia kazuistyczne itp.

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (text revision). Washington, DC, APA, 2000 [G]
2. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Revision). *Am. J. Psychiatry* 2000; 157 (April suppl) [G]
3. American Academy of Child and Adolescent Psychiatry: AACAP official action: practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. *J. Am. Acad. Child Adolesc. Psychiatry* 1997; 36:138–157 [G]
4. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., Rush A.J., Weissman M.M.: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. *Arch. Gen. Psychiatry* 1991; 48:851–855 [F]
5. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder. *Am. J. Psychiatry* 1994; 151 (Dec suppl) [G]
6. Hirschfeld R.M.A., Williams J.B.W., Spitzer R.L., Calabrese J.R., Flynn L., Keck P.E.Jr., Lewis L., McElroy S.L., Post R.M., Rapoport D.J., Russell J.M., Sachs G.S., Zajecka J.: Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. *Am. J. Psychiatry* 2000; 157:1873–1875 [G]
7. American Psychiatric Association: Practice Guideline for Psychiatric Evaluation of Adults. *Am. J. Psychiatry* 1995; 152 (Nov suppl) [G]
8. Isometsa E.T., Henriksson M.M., Aro H.M., Lonnqvist J.K.: Suicide in bipolar disorder in Finland. *Am. J. Psychiatry* 1994; 151:1020–1024 [D]
9. Dilsaver S.C., Chen Y.W., Swann A.C., Shoaib A.M., Krajewski K.J.: Suicidality in patients with pure and depressive mania. *Am. J. Psychiatry* 1994; 151:1312–1315 [D]
10. Strakowski S.M., McElroy S.L., Keck P.E. Jr., West S.A.: Suicidality among patients with mixed and manic bipolar disorder. *Am. J. Psychiatry* 1996; 153:674–676 [C]
11. Muller-Oerlinghausen B., Wolf T., Ahrens B., Glaenz T., Schou M., Grof E., Grof P., Lenz G., Simhandl C., Thau K., Vestergaard P., Wolf R.: Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-Treated Patients (IGSLI). *Acta Psychiatr. Scand.* 1996; 94:344–347 [C]
12. Baldessarini R.J., Tondo L., Hennen J.: Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. *J. Clin. Psychiatry* 1999; 60 (suppl 2): 77–84 [E]

13. Angst J., Preisig M.: Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients: results of a prospective study from 1959 to 1985. *Schweiz. Arch. Neurol. Psychiatr.* 1995; 146:17–23 [C]
14. Rosenfarb I.S., Miklowitz D.J., Goldstein M.J., Harmon L., Nuechterlein K.H., Rea M.M.: Family transactions and relapse in bipolar disorder. *Fam. Process* 2001; 40:5–14 [C]
15. Mino Y., Shimodera S., Inoue S., Fujita H., Tanaka S., Kanazawa S.: Expressed emotion of families and the course of mood disorders: a cohort study in Japan. *J. Affect. Disord.* 2001; 63:43–49 [C]
16. Tompson M.C., Rea M.M., Goldstein M.J., Miklowitz D.J., Weisman A.G.: Difficulty in implementing a family intervention for bipolar disorder: the predictive role of patient and family attributes. *Fam. Process* 2000; 39:105–120 [G]
17. Simoneau T.L., Miklowitz D.J., Saleem R.: Expressed emotion and interactional patterns in the families of bipolar patients. *J. Abnorm. Psychol.* 1998, 107:497–507 [G]
18. Jamison K.R., Gerner R.H., Goodwin F.K.: Patient and physician attitudes toward lithium: relationship to compliance. *Arch. Gen. Psychiatry* 1979; 36:866–869 [G]
19. Gutheil T.G.: The psychology of psychopharmacology. *Bull. Menninger Clin.* 1982; 46: 321–330 [G]
20. Jamison K.R.: Manic-depressive illness: the overlooked need for psychotherapy, in *Integrating Pharmacotherapy and Psychotherapy*. Washington, DC, American Psychiatric Press, 1991 [F]
21. Jamison K.R., Akiskal H.S.: Medication compliance in patients with bipolar disorder. *Psychiatr. Clin. North. Am.* 1983; 6:175–192 [F]
22. Pardes H., Kaufmann C.A., Pincus H.A., West A.: Genetics and psychiatry: past discoveries, current dilemmas, and future directions. *Am. J. Psychiatry* 1989; 146:435–443 [G]
23. Johnson S.L., Roberts J.E.: Life events and bipolar disorder: implications from biological theories. *Psychol. Bull.* 1995; 117: 434–449 [F]
24. Hammen C., Gitlin M.: Stress reactivity in bipolar patients and its relation to prior history of disorder. *Am. J. Psychiatry* 1997; 154: 856–857 [D]
25. Malkoff-Schwartz S., Frank E., Andersen B., Sherrill J.T., Siegel L., Patterson D., Kupfer D.J.: Stressful life events and social rhythm disruption in the onset of manic and depressive bipolar episodes: a preliminary investigation. *Arch. Gen. Psychiatry* 1998; 55:702–707 [D]
26. Leibenluft E., Suppes T.: Treating bipolar illness: focus on treatment algorithms and management of the sleep-wake cycle (case conf). *Am. J. Psychiatry* 1999; 156:1976–1986 [G]
27. Perry A., Tarrier N., Morriss R., McCarthy E., Limb K.: Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. *Br. Med. J.* 1999; 318:149–153 [A]
28. Butzlaff R.L., Hooley J.M.: Expressed emotion and psychiatric relapse: a meta-analysis. *Arch Gen Psychiatry* 1998; 55:547–552 [E]
29. Miklowitz D.J., Goldstein M.J., Nuechterlein K.H., Snyder K.S., Mintz J.: Family factors and the course of bipolar affective disorder. *Arch. Gen. Psychiatry* 1988; 45:225–231 [C]
30. Post R.M., Roy-Byrne P.P., Uhde T.W.: Graphic representation of the life course of illness in patients with affective disorder. *Am. J. Psychiatry* 1988; 145:844–848 [G]
31. Kraepelin E.: *Manic-Depressive Insanity and Paranoia* (1921). Translated by Barclay R.M., Salem N.H., Ayer. 1976 [G]
32. Meyer A.: *The Collected Papers of Adolph Meyer*. Baltimore, Johns Hopkins University Press, 1950 [G]
33. Tohen M., Hennen J., Zarate C.M. Jr, Baldessarini R.J., Strakowski S.M., Stoll A.L., Faedda G.L., Suppes T., Gebre-Medhin P., Cohen B.M.: Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. *Am. J. Psychiatry* 2000; 157:220–228 [D]
34. Suppes T., Leverich G.S., Keck P.E. Jr.: The Stanley Foundation Bipolar Network: demographics and illness characteristics of the first 261 patients with bipolar disorder. *J. Affect Disord* (in press) [C]

35. Keck P.E. Jr., McElroy S.L., Strakowski S.M., West S.A., Sax K.W., Hawkins J.M., Bourne M.L., Haggard P.: 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. *Am. J. Psychiatry* 1998; 155:646–652 [C]
36. Rossi A., Arduini L., Daneluzzo E., Bustini M., Prosperini P., Stratta P.: Cognitive function in euthymic bipolar patients, stabilized schizophrenic patients and healthy controls. *J. Psychiatr. Res.* 2000; 34:333–339 [G]
37. Bearden C.E., Hoffman K.M., Cannon T.D.: The neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. *Bipolar Disord.* 2001; 3:106–150 [F]
38. Howland R.H.: Induction of mania with serotonin reuptake inhibitors. *J. Clin. Psychopharmacol.* 1996; 16:425–427 [B]
39. Calabrese J.R., Suppes T., Bowden C.L., Sachs G.S., Swann A.C., McElroy S.L., Kusumakar V., Ascher J.A., Earl N.L., Greene P.L., Monaghan E.T. (Lamictal 614 Study Group): A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. *J. Clin. Psychiatry* 2000; 61:841–850 [A]
40. Calabrese J.R., Shelton M.D., Bowden C.L., Rapport D.J., Suppes T., Shirley E.R., Kimmel S.E., Caban S.J.: Bipolar rapid cycling: focus on depression as its hallmark. *J. Clin. Psychiatry* 2001; 62 (suppl 14): 34–41 [F]
41. Goodwin F.K., Jamison K.R.: *Manic-Depressive Illness*. New York, Oxford University Press, 1990 [G]
42. Carlson G.A., Bromet E.J., Sievers S.: Phenomenology and outcome of subjects with early- and adult-onset psychotic mania. *Am. J. Psychiatry* 2000; 157:213–219 [C]
43. Tohen M., Tsuang M.T., Goodwin D.C.: Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features. *Am. J. Psychiatry* 1992; 149:1580–1584 [C]
44. Fennig S., Bromet E.J., Karant M.T., Ram R., Jandorf L.: Mood-congruent versus mood-incongruent psychotic symptoms in first-admission patients with affective disorder. *J. Affect. Disord.* 1996; 37:23–29 [D]
45. McElroy S.L., Keck P.E. Jr., Strakowski S.M.: Mania, psychosis, and antipsychotics. *J. Clin. Psychiatry* 1996; 57 (suppl 3):14–26 [F]
46. Braunig P., Kruger S., Shugar G.: Prevalence and clinical significance of catatonic symptoms in mania. *Compr. Psychiatry* 1998; 39:35–46 [D]
47. Taylor M.A., Abrams R.: Catatonia: prevalence and importance in the manic phase of manic-depressive illness. *Arch. Gen. Psychiatry* 1977; 34:1223–1225 [C]
48. Hawkins J.M., Archer K.J., Strakowski S.M., Keck P.E.: Somatic treatment of catatonia. *Int. J. Psychiatry Med.* 1995; 25:345–369 [F]
49. Rosebush P.I., Hildebrand A.M., Furlong B.G., Mazurek M.F.: Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. *J. Clin. Psychiatry* 1990; 51:357–362 [B]
50. Northoff G., Wenke J., Demisch L., Eckert J., Gille B., Pflug B.: Catatonia: short-term response to lorazepam and dopaminergic metabolism. *Psychopharmacology (Berl)* 1995; 122:182–186 [B]
51. Bush G., Fink M., Petrides G., Dowling F., Francis A.: Catatonia, II: treatment with lorazepam and electroconvulsive therapy. *Acta Psychiatr. Scand.* 1996; 93:137–143 [B]
52. Lee J.W.: Serum iron in catatonia and neuroleptic malignant syndrome. *Biol. Psychiatry* 1998; 44: 499–507 [B]
53. Cooper T.B., Bergner P.E., Simpson G.M.: The 24-hour serum lithium level as a prognosticator of dosage requirements. *Am. J. Psychiatry* 1973; 130:601–603 [C]
54. Simpson S.G., Jamison K.R.: The risk of suicide in patients with bipolar disorders. *J. Clin. Psychiatry* 1999; 60 (suppl 2):53–56 [F]
55. Lester D.: Suicidal behavior in bipolar and unipolar affective disorders: a meta-analysis. *J. Affect. Disord.* 1993; 27:117–121 [E]
56. Tondo L., Baldessarini R.J.: Reduced suicide risk during lithium maintenance treatment. *J. Clin. Psychiatry* 2000; 61 (suppl 9): 97–104 [F]

57. Norton B., Whalley L.J.: Mortality of a lithium-treated population. *Br. J. Psychiatry* 1984; 145:277–282 [F]
58. Vieta E., Colom F., Martinez-Aran A., Benabarre A., Gasto C.: Personality disorders in bipolar II patients. *J. Nerv. Ment. Dis.*, 1999; 187:245–248 [G]
59. Fawcett J.: Treating impulsivity and anxiety in the suicidal patient. *Ann. NY Acad. Sci.* 2001; 932:94–102 [F]
60. Tondo L., Jamison K.R., Baldessarini R.J.: Effect of lithium maintenance on suicidal behavior in major mood disorders. *Ann. NY Acad. Sci.* 1997; 836:339–351 [E]
61. Ahrens B., Muller-Oerlinghausen B., Schou M., Wolf T., Alda M., Grof E., Grof P., Lenz G., Simhandl C., Thau K.: Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. *J. Affect. Disord.* 1995; 33:67–75 [D]
62. Brennan P.A., Mednick S.A., Hodgins S.: Major mental disorders and criminal violence in a Danish birth cohort. *Arch. Gen. Psychiatry* 2000; 57:494–500 [D]
63. Barlow K., Grenyer B., Ilkiw-Lavalle O.: Prevalence and precipitants of aggression in psychiatric inpatient units. *Aust. NZJ Psychiatry* 2000; 34:967–974 [C]
64. Asnis G.M., Kaplan M.L., Hundorfean G., Saeed W.: Violence and homicidal behaviors in psychiatric disorders. *Psychiatr. Clin. North. Am.* 1997; 20:405–425 [F]
65. Hendrick V., Altschuler L.L., Gitlin M.J., Delrahim S., Hammen C.: Gender and bipolar illness. *J. Clin. Psychiatry* 2000; 61:393–396 [D]
66. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K.: Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. *JAMA* 1990; 264:2511–2518 [D]
67. Regier D.A., Boyd J.H., Burke J.D. Jr., Rae D.S., Myers J.K., Kramer M., Robins L.N., George L.K., Karno M., Locke B.Z.: One-month prevalence of mental disorders in the United States: based on five Epidemiologic Catchment Area sites. *Arch. Gen. Psychiatry* 1988; 45:977–986 [D]
68. Tohen M., Waterman C.M., Tsuang M.T., Hunt A.T.: Four-year follow-up of twenty-four first-episode manic patients. *J. Affect. Disord.* 1990; 19:79–86 [C]
69. Tohen M., Waterman C.M., Tsuang M.T.: Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. *Arch. Gen. Psychiatry* 1990; 47:1106–1111 [C]
70. Potash J.B., Kane H.S., Chiu Y-F., Simpson S.G., MacKinnon D.F., McInnis M.G., McMahon F.J., DePaulo J.R. Jr.: Attempted suicide and alcoholism in bipolar disorder: clinical and familial relationships. *Am. J. Psychiatry* 2000; 157:2048–2050 [D]
71. Goldberg J.F., Gamo J.L., Leon A.C., Kocsis J.H., Portera L.: A history of substance abuse complicates remission from acute mania in bipolar disorder. *J. Clin. Psychiatry* 1999; 60:733–740 [D]
72. Sonne S.C., Brady K.T.: Substance abuse and bipolar comorbidity. *Psychiatr. Clin. North Am.* 1999; 22:609–627 [F]
73. Tondo L., Baldessarini R.J., Hennen J., Minnai G.P., Salis P., Scamonatti L., Masia M., Ghiani C., Mannu P.: Suicide attempts in major affective disorder patients with comorbid substance use disorders. *J. Clin. Psychiatry* 1999; 60 (suppl 2):63–69 [C]
74. Hagan H., Des J.: HIV and HCV infection among injecting drug users. *Mt Sinai J. Med.* 2000; 67:423–428 [F]
75. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Substance Use Disorders: Alcohol, Cocaine, Opioids. *Am. J. Psychiatry* 1995; 152 (Nov suppl) [G]
76. Dunayevich E., Sax K.W., Keck P.E. Jr., McElroy S.L., Sorter M.T., McConville B.J., Strakowski S.M.: Twelve-month outcome in bipolar patients with and without personality disorders. *J. Clin. Psychiatry* 2000; 61:134–139 [C]
77. Colom F., Vieta E., Martinez-Aran A., Reinares M., Benabarre A., Gasto C.: Clinical factors associated with treatment noncompliance in euthymic bipolar patients. *J. Clin. Psychiatry* 2000; 61: 549–555 [D]
78. Feske U., Frank E., Mallinger A.G., Houck P.R., Fagiolini A., Shear M.K., Grochocinski V.J., Kupfer D.J.: Anxiety as a correlate of response to the acute treatment of bipolar I disorder. *Am. J. Psychiatry* 2000; 157:956–962 [D]

79. Sachs G.S., Baldassano C.F., Truman C.J., Guille C.: Comorbidity of attention deficit hyperactivity disorder with early- and late-onset bipolar disorder. *Am. J. Psychiatry* 2000; 157:466–468 [G]
80. Johnston A.M., Eagles J.M.: Lithium-associated clinical hypothyroidism: prevalence and risk factors. *Br. J. Psychiatry* 1999; 175: 336–339 [C]
81. Leibenluft E.: Women with bipolar illness: clinical and research issues. *Am. J. Psychiatry* 1996; 153:163–173 [F]
82. Tondo L., Baldessarini R.J., Hennen J., Floris G., Silvetti F., Tohen M.: Lithium treatment and risk of suicidal behavior in bipolar disorder patients. *J. Clin. Psychiatry* 1998; 59:405–414 [B]
83. Dickson R.A., Seeman M.V., Corenblum B.: Hormonal side effects in women: typical versus atypical antipsychotic treatment. *J. Clin. Psychiatry* 2000; 61 (suppl 3): 10–15 [F]
84. Goodnick P.J., Chaudry T., Artadi J., Arcey S.: Women's issues in mood disorders. *Expert Opin. Pharmacother.* 2000; 1:903–916 [F]
85. Viguera A.C., Cohen L.S.: The course and management of bipolar disorder during pregnancy. *Psychopharmacol. Bull.* 1998; 34: 339–346 [F]
86. Altshuler L.L., Hendrick V., Cohen L.S.: Course of mood and anxiety disorders during pregnancy and the postpartum period. *J. Clin. Psychiatry* 1998; 59 (suppl 2):29–33 [F]
87. Rosenfeld W.E., Dooze D.R., Walker S.A., Nayak R.K.: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. *Epilepsia* 1997; 38:317–323 [B]
88. Wilbur K., Ensom M.H.: Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. *Clin. Pharmacokinet.* 2000; 38:355–365 [F]
89. Spina E., Pisani F., Perucca E.: Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. *Clin. Pharmacokinet.* 1996; 31:198–214 [F]
90. Potash J.B., DePaulo J.R. Jr.: Searching high and low: a review of the genetics of bipolar disorder. *Bipolar Disord.* 2000; 2:8–26 [F]
91. Berrettini W.H.: Genetics of psychiatric disease. *Annu. Rev. Med.* 2000; 51: 465–479 [F]
92. Duffy A., Grof P., Robertson C., Alda M.: The implications of genetics studies of major mood disorders for clinical practice. *J. Clin. Psychiatry* 2000; 61:630–637 [F]
93. Wisner K.L., Zarin D., Holmboe E., Appelbaum P., Gelenberg A.J., Leonard H.L., Frank E.: Risk-benefit decision making for treatment of depression during pregnancy. *Am. J. Psychiatry* 2000; 157: 1933–1940 [F]
94. Viguera A.C., Nonacs R., Cohen L.S., Tondo L., Murray A., Baldessarini R.J.: Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. *Am. J. Psychiatry* 2000; 157:179–184 [D]
95. Viguera A.C., Tondo L., Baldessarini R.J.: Sex differences in response to lithium treatment. *Am. J. Psychiatry* 2000; 157:1509–1511 [D]
96. Hoffman S., Hatch M.C.: Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. *Health Psychol.* 2000; 19:535–543 [C]
97. Paarlberg K.M., Vingerhoets A.J., Passchier J., Dekker G.A., Heinen A.G., van Geijn H.P.: Psychosocial predictors of low birthweight: a prospective study. *Br. J. Obstet. Gynaecol.* 1999; 106:834–841 [C]
98. Spielvogel A., Wile J.: Treatment and outcomes of psychotic patients during pregnancy and childbirth. *Birth* 1992; 19:131–137 [D]
99. Coverdale J.H., Chervenak F.A., McCullough L.B., Bayer T.: Ethically justified clinically comprehensive guidelines for the management of the depressed pregnant patient. *Am. J. Obstet. Gynecol.* 1996; 174:169–173 [F]
100. Stocky A., Lynch J.: Acute psychiatric disturbance in pregnancy and the puerperium. *Baillieres Best Pract. Res. Clin. Obstet. Gynaecol.* 2000; 14:73–87 [F]
101. Cohen L.S., Rosenbaum J.F.: Psychotropic drug use during pregnancy: weighing the risks. *J. Clin. Psychiatry* 1998; 59 (suppl 2): 18–28 [F]

102. Cohen L.S., Friedman J.M., Jefferson J.W., Johnson E.M., Weiner M.L.: A reevaluation of risk of in utero exposure to lithium. *JAMA* 1994; 271:146–150 [F]
103. Holmes L.B., Harvey E.A., Coull B.A., Huntington K.B., Khoshbin S., Hayes A.M., Ryan L.M.: The teratogenicity of anticonvulsant drugs. *N. Engl. J. Med.* 2001; 344:1132–1138 [C]
104. Arpino C., Brescianini S., Robert E., Castilla E.E., Cocchi G., Cornel M.C., de Vigan C., Lancaster P.A., Merlob P., Sumiyoshi Y., Zampino G., Renzi C., Rosano A., Mastroiacovo P.: Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). *Epilepsia* 2000; 41: 1436–1443 [C]
105. American Academy of Pediatrics Committee on Drugs: Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. *Pediatrics* 2000; 105:880–887 [F]
106. Wisner K.L., Gelenberg A.J., Leonard H., Zarin D., Frank E.: Pharmacologic treatment of depression during pregnancy. *JAMA* 1999; 282:1264–1269 [F]
107. Ericson A., Kallen B., Wiholm B.: Delivery outcome after the use of antidepressants in early pregnancy. *Eur. J. Clin. Pharmacol.* 1999; 55:503–508 [C]
108. McElhatton P.R.: The effects of benzodiazepine use during pregnancy and lactation. *Reprod. Toxicol.* 1994; 8:461–475 [F]
109. Dolovich L.R., Addis A., Vaillancourt J.M., Power J.D., Koren G., Einarson T.R.: Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. *Br. Med. J.* 1998; 317:839–843 [E]
110. American Psychiatric Association: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association, 2nd ed. Washington, DC, American Psychiatric Press 2001 [G]
111. Shnider S.M., Levinson G.: Anesthesia for Obstetrics, 3rd ed. Baltimore, Williams & Wilkins, 1993 [G]
112. Llewellyn A., Stowe Z.N., Strader J.R. Jr.: The use of lithium and management of women with bipolar disorder during pregnancy and lactation. *J. Clin. Psychiatry* 1998; 59 (suppl 6): 57–64 [F]
113. Cohen L.S., Sichel D.A., Robertson L.M., Heckscher E., Rosenbaum J.F.: Postpartum prophylaxis for women with bipolar disorder. *Am. J. Psychiatry* 1995; 152:1641–1645 [D]
114. Yoshida K., Smith B., Kumar R.: Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding. *J. Psychopharmacol.* 1999; 13:64–80 [F]
115. Chaudron L.H., Jefferson J.W.: Mood stabilizers during breast-feeding: a review. *J. Clin. Psychiatry* 2000; 61:79–90 [F]
116. Burt V.K., Suri R., Altshuler L., Stowe Z., Hendrick V.C., Muntean E.: The use of psychotropic medications during breast-feeding. *Am. J. Psychiatry* 2001; 158:1001–1009 [F]
117. Tomson T., Ohman I., Vitols S.: Lamotrigine in pregnancy and lactation: a case report. *Epilepsia* 1997; 38:1039–1041 [G]
118. American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk. *Pediatrics* 2001; 108:776–789 [F]
119. Strakowski S.M., McElroy S.L., Keck P.E. Jr., West S.A.: Racial influence on diagnosis in psychotic mania. *J. Affect. Disord.* 1996; 39:157–162 [D]
120. Strakowski S.M., Flaum M., Amador X., Bracha H.S., Pandurangi A.K., Robinson D., Tohen M.: Racial differences in the diagnosis of psychosis. *Schizophr. Res.*, 1996; 21:117–124 [D]
121. Strakowski S.M., Hawkins J.M., Keck P.E. Jr., McElroy S.L., West S.A., Bourne M.L., Sax K.W., Tugrul K.C.: The effects of race and information variance on disagreement between psychiatric emergency service and research diagnoses in first-episode psychosis. *J. Clin. Psychiatry* 1997; 58:457–463 [D]
122. Lin K.M., Anderson D., Poland R.E.: Ethnicity and psychopharmacology: bridging the gap. *Psychiatr. Clin. North. Am.* 1995; 18: 635–647 [F]
123. Bertilsson L.: Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. *Clin. Pharmacokinet.* 1995; 29:192–209 [F]

124. Lewinsohn P.M., Klein D.N., Seeley J.R.: Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. *J. Am. Acad. Child. Adolesc. Psychiatry* 1995; 34:454–463 [C]
125. Geller B., Zimmerman B., Williams M., Bolhofner K., Craney J.L., DelBello M.P., Soutullo C.A.: Diagnostic characteristics of 93 cases of a prepubertal and early adolescent bipolar disorder phenotype by gender, puberty and comorbid attention deficit hyperactivity disorder. *J. Child. Adolesc. Psychopharmacol.* 2000; 10, 157–164 [C]
126. Kovacs M., Pollock M.: Bipolar disorder and comorbid conduct disorder in childhood and adolescence. *J. Am. Acad. Child. Adolesc. Psychiatry* 1995; 34:715–723 [C]
127. West S.A., McElroy S.L., Strakowski S.M., Keck P.E. Jr., McConville B.J.: Attention deficit hyperactivity disorder in adolescent mania. *Am. J. Psychiatry* 1995; 152:271–273 [D]
128. Faraone S.V., Biederman J., Wozniak J., Mundy E., Mennin D., O'Donnell D.: Is comorbidity with ADHD a marker for juvenile-onset mania? *J. Am. Acad. Child. Adolesc. Psychiatry* 1997; 36: 1046–1055 [D]
129. Altshuler L.L., Cohen L.S., Moline M.L., Kahn D.A., Carpenter D., Docherty J.P.: The Expert Consensus Guideline Series: Treatment of Depression in Women. New York. McGraw-Hill Companies, 2001 [F]
130. Strober M., Schmidt-Lackner S., Freeman R., Bower S., Lampert C., DeAntonio M.: Recovery and relapse in adolescents with bipolar affective illness: a five-year naturalistic, prospective follow-up. *J. Am. Acad. Child. Adolesc. Psychiatry* 1995; 34:724–731 [C]
131. Biederman J., Mick E., Bostic J.Q., Prince J., Daly J., Wilens T.E., Spencer T., Garcia-Jetton J., Russell R., Wozniak J., Faraone S.V.: The naturalistic course of pharmacologic treatment of children with manic-like symptoms: a systematic chart review. *J. Clin. Psychiatry* 1998; 59:628–637 [B]
132. Strober M., Morrell W., Lampert C., Burroughs J.: Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness: a naturalistic study. *Am. J. Psychiatry* 1990; 147:457–461 [C]
133. Biederman J., Faraone S.V., Wozniak J., Monuteaux M.C.: Parsing the association between bipolar, conduct, and substance use disorders: a familial risk analysis. *Biol. Psychiatry* 2000; 48: 1037–1044 [C]
134. Wilens T.E., Biederman J., Millstein R.B., Wozniak J., Haesly A.L., Spencer T.J.: Risk for substance use disorders in youths with child- and adolescent-onset bipolar disorder. *J. Am. Acad. Child. Adolesc. Psychiatry* 1999; 38:680–685 [C]
135. Carlson G.A., Lavelle J., Bromet E.J.: Medication treatment in adolescents vs adults with psychotic mania. *J. Child. Adolesc. Psychopharmacol.* 1999; 9:221–231 [C]
136. Geller B., Luby J.: Child and adolescent bipolar disorder: a review of the past 10 years. *J. Am. Acad. Child. Adolesc. Psychiatry* 1997; 36:1168–1176; correction, 36:1642 [F]
137. Donovan S.J., Nunes E.V.: Treatment of comorbid affective and substance use disorders: the therapeutic potential of anticonvulsants. *Am. J. Addict.* 1998; 7:210–220 [F]
138. Van Gerpen M.W., Johnson J.E., Winstead D.K.: Mania in the geriatric patient population: a review of the literature. *Am. J. Geriatr. Psychiatry* 1999; 7:188–202 [F]
139. Young R.C., Klerman G.L.: Mania in late life: focus on age at onset. *Am. J. Psychiatry* 1992; 149:867–876 [F]
140. Shulman K.I., Herrmann N.: The nature and management of mania in old age. *Psychiatr. Clin. North. Am.* 1999; 22:649–665 [F]
141. Tohen M., Shulman K.I., Satlin A.: First-episode mania in late life. *Am. J. Psychiatry* 1994; 151:130–132 [C]
142. Sproule B.A., Hardy B.G., Shulman K.I.: Differential pharmacokinetics of lithium in elderly patients. *Drugs Aging* 2000; 16:165–177 [F]
143. Caligiuri M.R., Jeste D.V., Lacro J.P.: Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. *Drugs Aging* 2000; 17:363–384 [F]
144. Leipzig R.M., Cumming R.G., Tinetti M.E.: Drugs and falls in older people: a systematic review and meta-analysis, I: psychotropic drugs. *J. Am. Geriatr. Soc.* 1999; 47:30–39 [E]

145. Strakowski S.M., McElroy S.L., Keck P.W. Jr., West S.A.: The co-occurrence of mania with medical and other psychiatric disorders. *Int. J. Psychiatry. Med.* 1994; 24:305–328 [F]
146. Peet M., Peters S.: Drug-induced mania. *Drug Saf.* 1995; 12:146–153 [F]
147. Cozza K.L., Armstrong S.C. (red.): *Concise Guide to the Cytochrome P450 System: Drug Interaction Principles for Medical Practice*. Washington, DC, American Psychiatric Press, 2001, 103–200 [G]
148. American Psychiatric Association: Practice Guideline for the Treatment of Patients With HIV/AIDS. *Am. J. Psychiatry* 2000; 157 (Nov suppl) [G]
149. Akiskal H.S., Pinto O.: The evolving bipolar spectrum: prototypes I, II, III, and IV. *Psychiatr. Clin. North Am.* 1999; 22:517–534 [F]
150. Swann A.C., Bowden C.L., Calabrese J.R., Dilsaver S.C., Morris D.D.: Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. *Am. J. Psychiatry* 1999; 156:1264–1266 [E]
151. Lish J.D., Dime-Meenan S., Whybrow P.C., Price R.A., Hirschfeld R.M.: The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. *J. Affect. Disord* 1994; 31: 281–294 [G]
152. Manning J.S., Haykal R.F., Connor P.D., Akiskal H.S.: On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. *Compr. Psychiatry* 1997; 38:102–108 [D]
153. Perugi G., Akiskal H.S., Lattanzi L., Ceconi D., Mastrocinque C., Patronelli A., Vignoli S., Beml E.: The high prevalence of “soft” bipolar (II) features in atypical depression. *Compr. Psychiatry* 1998; 39:63–71 [G]
154. Benazzi F.: Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. *J. Affect. Disord.* 1997; 43:163–166 [G]
155. Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Keller M., Warshaw M., Clayton P., Goodwin F.: Switching from “unipolar” to bipolar II: an 11-year prospective study of clinical and temperamental predictors in 559 patients. *Arch. Gen. Psychiatry* 1995; 52:114–123 [C]
156. Mitchell P.B., Wilhelm K., Parker G., Austin M.P., Rutgers P., Malhi G.S.: The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. *J. Clin. Psychiatry* 2001; 62:212–216 [D]
157. Ghaemi S.N., Sachs G.S., Chiou A.M., Pandurangi A.K., Goodwin K.: Is bipolar disorder still underdiagnosed? are antidepressants overutilized? *J. Affect. Disord.* 1999; 52:135–144 [G]
158. Fogarty F., Russell J.M., Newman S.C., Bland R.C.: Epidemiology of psychiatric disorders in Edmonton: mania. *Acta Psychiatr. Scand. Suppl* 1994; 376:16–23 [G]
159. Faedda G.L., Baldessarini R.J., Suppes T., Tondo L., Becker I., Lipschitz D.S.: Pediatric-onset bipolar disorder: a neglected clinical and public health problem. *Harv. Rev. Psychiatry* 1995; 3:171–195 [F]
160. Winokur G., Coryell W., Akiskal H.S., Endicott J., Keller M., Mueller T.: Manic-depressive (bipolar) disorder: the course in light of a prospective ten-year follow-up of 131 patients. *Acta. Psychiatr. Scand* 1994; 89:102–110 [C]
161. Dion G.L., Tohen M., Anthony W.A., Waternaux C.S.: Symptoms and functioning of patients with bipolar disorder six months after hospitalization. *Hosp. Community Psychiatry* 1988; 39:652–657 [C]
162. Goodnick P.J., Fieve R.R., Schlegel A., Baxter N.: Predictors of interepisode symptoms and relapse in affective disorder patients treated with lithium carbonate. *Am. J. Psychiatry* 1987; 144:367–369 [B]
163. Goldberg J.F., Harrow M., Grossman L.S.: Course and outcome in bipolar affective disorder: a longitudinal follow-up study. *Am. J. Psychiatry* 1995; 152:379–384 [C]
164. Coryell W., Scheftner W., Keller M., Endicott J., Maser J., Klerman G.L.: The enduring psychosocial consequences of mania and depression. *Am. J. Psychiatry* 1993; 150:720–727 [C]
165. Weissman M.M., Bland R.C., Canino G.J., Faravelli C., Greenwald S., Hwu H.G., Joyce P.R., Karam E.G., Lee C.K., Lellouch J., Lepine J.P., Newman S.C., Rubio-Stipec M., Wells J.E.,

- Wickramaratne P.J., Wittchen H., Yeh E.K.: Cross-national epidemiology of major depression and bipolar disorder. *JAMA* 1996; 276:293–299 [E]
166. Angst J.: The emerging epidemiology of hypomania and bipolar II disorder. *J. Affect. Disord.* 1998; 50:143–151 [C]
167. Geller B., Craney J.L., Bolhofner K., DelBello M.P., Williams M., Zimmerman B.: One-year recovery and relapse rates of children with a prepubertal and early adolescent bipolar disorder phenotype. *Am. J. Psychiatry* 2001; 158:303–305 [C]
168. McDonald W.M., Nemeroff C.B.: The diagnosis and treatment of mania in the elderly. *Bull. Menninger Clin.* 1996; 60:174–196 [F]
169. Tohen M., Bromet E., Murphy J.M., Tsuang M.T.: Psychiatric epidemiology. *Harvard Rev. Psychiatry* 2000; 8:111–125 [G]
170. Leverich G.S., McElroy S.L., Suppes T.: Early physical or sexual abuse and the course of bipolar illness. *Biological Psychiatry* (in press) [G]
171. Johnson S.L., Miller I.: Negative life events and time to recovery from episodes of bipolar disorder. *J. Abnorm. Psychol.* 1997; 106:449–457 [C]
172. Frank E., Thase M.E.: Natural history and preventative treatment of recurrent mood disorders. *Annu. Rev. Med.* 1999; 50:453–468 [F]
173. Colombo C., Benedetti F., Barbini B., Campori E., Smeraldi E.: Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. *Psychiatry Res.* 1999; 86: 267–270 [B]
174. Ashman S.B., Monk T.H., Kupfer D.J., Clark C.H., Myers F.S., Frank E., Leibenluft E.: Relationship between social rhythms and mood in patients with rapid cycling bipolar disorder. *Psychiatry Res.* 1999; 86:1–8 [C]
175. Strakowski S.M., DelBello M.P.: The co-occurrence of bipolar and substance use disorders. *Clin. Psychol. Rev.* 2000; 20:191–206 [F]
176. Schou M., Juel-Nielsen, Stroomgren E., Voldby H.: The treatment of manic psychoses by administration of lithium salts. *J. Neurol. Neurosurg. Psychiatry* 1954; 17:250–260 [B]
177. Goodwin F.K., Murphy D.L., Bunney W.E. Jr.: Lithium-carbonate treatment in depression and mania: a longitudinal double-blind study. *Arch. Gen. Psychiatry* 1969; 21:486–496 [B]
178. Stokes P.E., Shamoian C.A., Stoll P.M., Patton M.J.: Efficacy of lithium as acute treatment of manic-depressive illness. *Lancet* 1971; 1:1319–1325 [B]
179. Maggs R.: Treatment of manic illness with lithium carbonate. *Br. J. Psychiatry* 1963; 109: 56–65 [B]
180. Bowden C.L., Brugger A.M., Swann A.C., Calabrese J.R., Janicak P.G., Petty F., Dilsaver S.C., Davis J.M., Rush A.J., Small J.G., (Depakote Mania Study Group): Efficacy of divalproex vs lithium and placebo in the treatment of mania. *JAMA* 1994; 271:918–924 [A]
181. Lerer B., Moore N., Meyendorff E., Cho S.R., Gershon S.: Carbamazepine versus lithium in mania: a double-blind study. *J. Clin. Psychiatry* 1987; 48:89–93 [A]
182. Small J.G., Klapper M.H., Milstein V., Kellams J.J., Miller M.J., Marhenke J.D., Small I.F.: Carbamazepine compared with lithium in the treatment of mania. *Arch. Gen. Psychiatry* 1991; 48:915–921 [A]
183. Segal J., Berk M., Brook S.: Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. *Clin. Neuropharmacol* 1998; 21:176–180 [A]
184. Berk M., Ichim L., Brook S.: Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. *Int. Clin. Psychopharmacol* 1999; 14:339–343 [A]
185. Takahashi R., Sakuma A., Itoh K., Itoh H., Kurihara M.: Comparison of efficacy of lithium carbonate and chlorpromazine in mania: report of collaborative study group on treatment of mania in Japan. *Arch. Gen. Psychiatry* 1975; 32:1310–1318 [A]
186. Platman S.R.: A comparison of lithium carbonate and chlorpromazine in mania. *Am. J. Psychiatry* 1970; 127:351–353 [A]
187. Spring G., Schweid D., Gray C., Steinberg J., Horwitz M.: A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. *Am. J. Psychiatry* 1970; 126:1306–1310 [A]

188. Johnson G., Gershon S., Burdock E.I., Floyd A., Hekimian L.: Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. *Br. J. Psychiatry* 1971; 119: 267–276 [A]
189. Prien R.F., Caffey E.M. Jr., Klett C.J.: Comparison of lithium carbonate and chlorpromazine in the treatment of mania: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. *Arch. Gen. Psychiatry* 1972; 26:146–153 [A]
190. Shopsin B., Gershon S., Thompson H., Collins P.: Psychoactive drugs in mania: a controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. *Arch. Gen. Psychiatry* 1975; 32:34–42 [A]
191. Secunda S.K., Katz M.M., Swann A., Koslow S.H., Maas J.W., Chuang S., Croughan J.: Mania: diagnosis, state measurement and prediction of treatment response. *J. Affect. Disord.* 1985; 8:113–121 [E]
192. Himmelhoch J.M., Garfinkel M.E.: Sources of lithium resistance in mixed mania. *Psychopharmacol. Bull.* 1986; 22:613–620 [C]
193. Prien R.F., Himmelhoch J.M., Kupfer D.J.: Treatment of mixed mania. *J. Affect. Disord.* 1988; 15:9–15 [B]
194. Kramlinger K.G., Post R.M.: Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania. *Acta Psychiatr. Scand.* 1989; 79:378–385 [B]
195. Freeman T.W., Clothier J.L., Pazzaglia P., Lesem M.D., Swann A.C.: A double-blind comparison of valproate and lithium in the treatment of acute mania. *Am. J. Psychiatry* 1992; 149:108–111 [A]
196. Bowden C.L.: Predictors of response to divalproex and lithium. *J. Clin. Psychiatry* 1995; 56 (suppl 3):25–30 [E]
197. Swann A.C., Bowden C.L., Morris D., Calabrese J.R., Petty F., Small J., Dilsaver S.C., Davis J.M.: Depression during mania: treatment response to lithium or divalproex. *Arch. Gen. Psychiatry* 1997; 54: 37–42 [E]
198. Jefferson J.W., Greist J.H., Acherman D.L., Carroll J.A.: *Lithium Encyclopedia for Clinical Practice*, 2nd ed. Washington, DC, American Psychiatric Press, 1987 [F]
199. Schou M.: Lithium prophylaxis: myths and realities. *Am. J. Psychiatry* 1989; 146:573–576 [F]
200. Peet M., Pratt J.P.: Lithium: current status in psychiatric disorders. *Drugs* 1993; 46:7–17 [F]
201. Burggraf G.W.: Are psychotropic drugs at therapeutic levels a concern for cardiologists? *Can. J. Cardiol.*, 1997; 13:75–80 [F]
202. Gitlin M.: Lithium and the kidney: an updated review. *Drug Saf.* 1999; 20:231–243 [F]
203. Bendz H., Aurell M.: Drug-induced diabetes insipidus: incidence, prevention and management. *Drug Saf.* 1999; 21:449–456 [F]
204. Arana G.W., Hyman S.E.: *Handbook of Psychiatric Drug Therapy*, 2nd ed. Boston, Little, Brown, 1991 [F]
205. Bauer M.S., Whybrow P.C.: Rapid cycling bipolar affective disorder, II: treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. *Arch. Gen. Psychiatry* 1990; 47:435–440 [A]
206. Kleiner J., Altshuler L., Hendrick V., Hershman J.M.: Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. *J. Clin. Psychiatry* 1999; 60: 249–255 [F]
207. Smigán L., Wahlin A., Jacobsson L., von Knorring L.: Lithium therapy and thyroid function tests: a prospective study. *Neuropsychobiology* 1984; 11:39–43 [B]
208. Bocchetta A., Bernardi F., Burrai C., Pedditzi M., Loviselli A., Velluzzi F., Martino E., Del Zompo M.: The course of thyroid abnormalities during lithium treatment: a two-year follow-up study. *Acta Psychiatr. Scand.* 1992; 86:38–41 [C]
209. Haden S.T., Stoll A.L., McCormick S., Scott J., Fuleihan G.E.-H.: Alterations in parathyroid dynamics in lithium-treated subjects. *J. Clin. Endocrinol. Metab.* 1997; 82: 2844–2848 [B]
210. Kallner G., Petterson U.: Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1–30 years. *Acta Psychiatr. Scand.* 1995; 91:48–51 [C]

211. Mak T.W., Shek C.C., Chow C.C., Wing Y.K., Lee S.: Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. *J. Clin. Endocrinol. Metab.* 1998; 83: 3857–3859 [B]
212. Chan H.H., Wing Y., Su R., Van Krevel C., Lee S.: A control study of the cutaneous side effects of chronic lithium therapy. *J. Affect. Disord.* 2000; 57:107–113 [D]
213. Vestergaard P., Schou M., Thomsen K.: Monitoring of patients in prophylactic lithium treatment: an assessment based on recent kidney studies. *Br. J. Psychiatry* 1982; 140:185–187 [C]
214. Schou M.: Effects of long-term lithium treatment on kidney function: an overview. *J. Psychiatr. Res.* 1988; 22:287–296 [F]
215. Gitlin M.J.: Lithium-induced renal insufficiency. *J. Clin. Psychopharmacol.* 1993; 13: 276–279 [C]
216. Bendz H., Sjodin I., Aurell M.: Renal function on and off lithium in patients treated with lithium for 15 years or more: a controlled, prospective lithium-withdrawal study. *Nephrol. Dial. Transplant.* 1996; 11:457–460 [B]
217. von Knorring L., Walton S.A., Okuma T., Bohman S.O.: Uraemia induced by long-term lithium treatment. *Lithium* 1990; 1:251–253 [G]
218. Markowitz G.S., Radhakrishnan J., Kambham N., Valeri A.M., Hines W.H., D'Agati V.D.: Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. *J. Am. Soc. Nephrol.* 2000; 11:1439–1448 [G]
219. Ellenhorn M.J.: Lithium, in *Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning*. Baltimore, Williams & Wilkins 1997; 1579–1585 [G]
220. Scharman E.J.: Methods used to decrease lithium absorption or enhance elimination. *J. Toxicol. Clin. Toxicol.* 1997; 35:601–608 [F]
221. Jaeger A., Sauder P., Kopferschmitt J., Tritsch L., Flesch F.: When should dialysis be performed in lithium poisoning? a kinetic study in 14 cases of lithium poisoning. *J. Toxicol. Clin. Toxicol.* 1993; 31:429–447 [B]
222. van Bommel E.F., Kalmeijer M.D., Ponssen H.H.: Treatment of life-threatening lithium toxicity with high-volume continuous venovenous hemofiltration. *Am. J. Nephrol.* 2000; 20:408–411 [G]
223. Friedberg R.C., Spyker D.A., Herold D.A.: Massive overdoses with sustained-release lithium carbonate preparations: pharmacokinetic model based on two case studies. *Clin. Chem.* 1991; 37: 1205–1209 [G]
224. Bosse G.M., Arnold T.C.: Overdose with sustained-release lithium preparations. *J. Emerg. Med.* 1992; 10:719–721 [G]
225. Gelenberg A.J., Kane J.M., Keller M.B., Lavori P., Rosenbaum J.F., Cole K., Lavelle J.: Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. *N. Engl. J. Med.* 1989; 321:1489–1493 [A]
226. Vestergaard P., Licht R.W., Brodersen A., Rasmussen N.A., Christensen H., Arnglim T., Gronvall B., Kristensen E., Poulstrup I., Wentzer L.R.: Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. *Acta Psychiatr. Scand.* 1998; 98:310–315 [B]
227. Emrich H.M., von Zerssen D., Kissling W.: On a possible role of GABA in mania: therapeutic efficacy of sodium valproate, in *GABA and Benzodiazepine Receptors*. Edited by Costa E., Dicharia G, Gessa GL. New York, Raven Press, 1981, 287–296 [B]
228. Brennan M.J.W., Sandyk R., Borsook D.: Use of sodium valproate in the management of affective disorders: basic and clinical aspects, in *Anticonvulsants in Affective Disorders*. Edited by Emrich H.M., Okuma T., Muller A.A. Amsterdam, Excerpta Medica, 1984, 56–65 [A]
229. Pope H.G. Jr., McElroy S.L., Keck P.E. Jr., Hudson J.I.: Valproate in the treatment of acute mania: a placebo-controlled study. *Arch. Gen. Psychiatry* 1991; 48:62–68 [A]
230. McElroy S.L., Keck P.E., Stanton S.P., Tugrul K.C., Bennett J.A., Strakowski S.M.: A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. *J. Clin. Psychiatry* 1996; 57:142–146 [B]

231. Zajecka J.M., Weisler R., Swann A.C.: Divalproex sodium versus olanzapine for the treatment of mania in bipolar disorder, in American College of Neuropsychopharmacology Annual Meeting Poster Abstracts. Nashville, Tenn, ACNP, 2000 [A]
232. Tohen M.F., Milton D.R., Davis A.R.: Olanzapine versus divalproex for the treatment of acute mania, in Congress Poster Abstracts. Munich, European College of Neuropsychopharmacology, 2000 [A]
233. Sheth R.D., Wesolowski C.A., Jacob J.C., Penney S., Hobbs G.R., Riggs J.E., Bodensteiner J.B.: Effect of carbamazepine and valproate on bone mineral density. *J. Pediatr.* 1995; 127: 256–262 [D]
234. Tannirandorn P., Epstein S.: Drug-induced bone loss. *Osteoporos. Int.* 2000; 11:637–659 [F]
235. Davis R., Peters D.H., McTavish D.: Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. *Drugs* 1994; 47:332–372 [F]
236. Mercke Y., Sheng H., Khan T., Lippmann S.: Hair loss in psychopharmacology. *Ann. Clin. Psychiatry* 2000; 12:35–42 [F]
237. Gautam M.: Alopecia due to psychotropic medications. *Ann. Pharmacother.* 1999; 33: 631–637 [F]
238. Stoll A.L., Walton S.A., McElroy S.L.: Histamine-2-receptor antagonists for the treatment of valproate-induced gastrointestinal distress. *Ann. Clin. Psychiatry* 1991; 3:301–304 [G]
239. Spiller H.A., Krenzelok E.P., Klein-Schwartz W., Winter M.L., Weber J.A., Sollee D.R., Bangh S.A.: Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. *J. Toxicol. Clin. Toxicol.* 2000; 38:755–760 [G]
240. Loscher W.: Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. *Prog. Neurobiol.* 1999; 58:31–59 [F]
241. Bryant A.E. III, Dreifuss F.E.: Valproic acid hepatic fatalities, III: US experience since 1986. *Neurology* 1996; 46:465–469 [B]
242. Gidal B., Spencer N., Maly M., Pitterle M., Williams E., Collins M., Jones J.: Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. *Neurology* 1994; 44:1418–1422 [C]
243. Finsterer J., Pelzl G., Hess B.: Severe, isolated thrombocytopenia under polytherapy with carbamazepine and valproate. *Psychiatry Clin. Neurosci.* 2001; 55:423–426 [G]
244. Chappell K.A., Markowitz J.S., Jackson C.W.: Is valproate pharmacotherapy associated with polycystic ovaries? *Ann. Pharmacother.* 1999; 33:1211–1216 [F]
245. Genton P., Bauer J., Duncan S., Taylor A.E., Balen A.H., Eberle A., Pedersen B., Salas-Puig X., Sauer M.V.: On the association between valproate and polycystic ovary syndrome. *Epilepsia* 2001; 42:295–304 [F]
246. Joffe H., Taylor A.E., Hall J.E.: Polycystic ovarian syndrome-relationship to epilepsy and antiepileptic drug therapy. *J. Clin. Endocrinol. Metab.* 2001; 86:2946–2949 [F]
247. Isojarvi J.I., Laatikainen T.J., Pakarinen A.J., Juntunen K.T., Myllyla V.V.: Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. *N. Engl. J. Med.* 1993; 329:1383–1388 [G]
248. Ellenhorn M.J.: Valproate, in Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Baltimore, Williams & Wilkins, 1997, 610–612 [G]
249. Janicak P., Davis J.M., Preskorn S.H., Ayd F.J.: Principles and Practice of Psychopharmacotherapy. Baltimore, Williams & Wilkins, 1993 [F]
250. Gilman A.G., Rall T.W., Nies A.S., Taylor P. (red): Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. New York, Pergamon Press, 1990 [G]
251. Keck P.E. Jr., McElroy S.L., Tugrul K.C., Bennett J.A.: Valproate oral loading in the treatment of acute mania. *J. Clin. Psychiatry* 1993; 54:305–308 [B]
252. McElroy S.L., Keck P.E. Jr., Tugrul K.C., Bennett J.A.: Valproate as a loading treatment in acute mania. *Neuropsychobiology* 1993; 27:146–149 [G]
253. Martinez J.M., Russell J.M., Hirschfeld R.M.: Tolerability of oral loading of divalproex sodium in the treatment of acute mania. *Depress. Anxiety* 1998; 7:83–86 [D]

254. Hirschfeld R.M., Allen M.H., McEvoy J.P., Keck P.E. Jr., Russell J.M.: Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. *J. Clin. Psychiatry* 1999; 60:815–818 [A]
255. Longo L.P.: Divalproex sodium for alcohol withdrawal and relapse prevention: a case report. *J. Clin. Psychiatry* 2000; 61:947–948 [G]
256. Horne M., Lindley S.E.: Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes (letter). *J. Clin. Psychiatry* 1995; 56:430–431 [G]
257. Miller P.R.: Clozapine therapy for a patient with a history of Hodgkin's disease (letter). *Psychiatr. Serv.* 2001; 52:110–111 [G]
258. Pellock J.M., Willmore L.J.: A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. *Neurology* 1991; 41:961–964 [G]
259. McElroy S.L., Keck P.E. Jr., Pope H.G., Jr, Hudson J.I.: Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. *J. Clin. Psychopharmacol.* 1992; 12:42S–52S [F]
260. McElroy S.L., Keck P.E. Jr., Pope H.G. Jr., Hudson J.I., Faedda G.L., Swann A.C.: Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. *Am. J. Psychiatry* 1992; 149:1633–1644 [F]
261. Riva R., Albani F., Contin M., Baruzzi A.: Pharmacokinetic interactions between antiepileptic drugs: clinical considerations. *Clin. Pharmacokinet.* 1996; 31:470–493 [F]
262. Matsuo F.: Lamotrigine. *Epilepsia* 1999; 40 (suppl 5):S30–S36 [F]
263. Tanaka E.: Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. *J. Clin. Pharmacol. Ther.* 1999; 24:87–92 [F]
264. Keck P.E. Jr., McElroy S.L., Nemeroff C.B.: Anticonvulsants in the treatment of bipolar disorder. *J. Neuropsychiatry Clin. Neurosci.* 1992; 4:395–405 [F]
265. Ballenger J.C., Post R.M.: Therapeutic effects of carbamazepine in affective illness: a preliminary report. *Commun. Psychopharmacol.* 1978; 2:159–175 [A]
266. Vasudev K., Goswami U., Kohli K.: Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. *Psychopharmacology (Berl)* 2000; 150:15–23 [A]
267. Grossi E., Sacchetti E., Vita A.: Anticonvulsants in affective disorders, in Carbamazepine Versus Chlorpromazine in Mania: A Double-Blind Trial. Edited by Emirch H.M., Okuma T., Muller A.A. Amsterdam, Excerpta Medica, 1984, 177–187 [B]
268. Okuma T., Inanaga K., Otsuki S., Sarai K., Takahashi R., Hazama H., Mori A., Watanabe M.: Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. *Psychopharmacology (Berl)* 1979; 66:211–217 [A]
269. Rimmer E.M., Richens A.: An update on sodium valproate. *Pharmacotherapy* 1985; 5: 171–184 [F]
270. Smith M.C., Bleck T.P.: Convulsive disorders: toxicity of anticonvulsants. *Clin. Neuropharmacol.* 1991; 14:97–115 [F]
271. Kramlinger K.G., Phillips K.A., Post R.M.: Rash complicating carbamazepine treatment. *J. Clin. Psychopharmacol.* 1994; 14: 408–413 [C]
272. Van Amelsvoort T., Bakshi R., Devaux C.B., Schwabe S.: Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. *Epilepsia* 1994; 35:181–188 [F]
273. Seetharam M.N., Pellock J.M.: Risk-benefit assessment of carbamazepine in children. *Drug Saf.* 1991; 6:148–158 [F]
274. Knowles S.R., Shapiro L.E., Shear N.H.: Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. *Drug Saf.* 1999; 21:489–501 [F]
275. Schweiger F.J., Kelton J.G., Messner H., Klein M., Berger S., McIlroy W.J., Falk J., Keating A.: Anticonvulsant-induced marrow suppression and immune thrombocytopenia. *Acta Haematol.* 1988; 80:54–58 [G]
276. Ketter T.A., Frye M.A., Cora-Locatelli G., Kimbrell T.A., Post R.M.: Metabolism and excretion of mood stabilizers and new anticonvulsants. *Cell. Mol. Neurobiol.* 1999; 19:511–532 [F]

277. Muller A.A., Stoll K.D.: Anticonvulsants in affective disorders, in Carbamazepine and Oxcarbazepine in the Treatment of Manic Syndromes: Studies in Germany. Edited by Emrich H.M., Okuma T., Muller A.A. Amsterdam, Excerpta Medica 1984, 134–147 [B]
278. Emrich H.M., Zihl J., Raptis C., Wendl A.: Reduced dark-adaptation: an indication of lithium's neuronal action in humans. *Am. J. Psychiatry* 1990; 147:629–631 [G]
279. Dam M., Ekberg R., Loyning Y., Waltimo O., Jakobsen K.: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. *Epilepsy Res.* 1989; 3:70–76 [A]
280. Glauser T.A., Nigro M., Sachdeo R., Pasteris L.A., Weinstein S., Abou-Khalil B., Frank L.M., Grinspan A., Guarino T., Bettis D., Kerrigan J., Geoffroy G., Mandelbaum D., Jacobs T., Mesenbrink P., Kramer L., D'Souza J. (Oxcarbazepine Pediatric Study Group): Adjunctive therapy with oxcarbazepine in children with partial seizures. *Neurology* 2000; 54:2237–2244 [A]
281. Smith P.E.: Clinical recommendations for oxcarbazepine. *Seizure* 2001; 10:87–91 [F]
282. Wellington K., Goa K.L.: Oxcarbazepine: an update of its efficacy in the management of epilepsy. *CNS Drugs* 2001; 15:137–163 [F]
283. Suppes T., Swann A.C., Dennehy E.B., Habermacher E.D., Mason M., Crismon M.L., Toprac M.G., Rush A.J., Shon S.P., Altschuler K.Z.: Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. *J. Clin. Psychiatry* 2001; 62:439–447 [B]
284. Frye M.A., Ketter T.A., Kimbrell T.A., Dunn R.T., Speer A.M., Osuch E.A., Luckenbaugh D.A., Cora-Locatelli G., Leverich G.S., Post R.M.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. *J. Clin. Psychopharmacol.* 2000; 20:607–614 [A]
285. Anand A., Oren D.A., Berman R.M.: Lamotrigine treatment of lithium failure in outpatient mania: a double-blind, placebo-controlled trial, in Abstract Book, Third International Bipolar Conference. (red) Soares J.C., Gershon S. Pittsburgh, Munks-gaard, 1999, 23 [A]
286. Ichim L., Berk M., Brook S.: Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. *Ann. Clin. Psychiatry* 2000; 12:5–10 [A]
287. Pande A.C., Crockatt J.G., Janney C.A., Werth J.L., Tsaroucha G. (Gabapentin Bipolar Disorder Study Group): Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. *Bipolar Disord.* 2000; 2:249–255 [A]
288. Mishory A., Yaroslavsky Y., Bersudsky Y., Belmaker R.H.: Phenytoin as an antimanic anti-convulsant: a controlled study. *Am. J. Psychiatry* 2000; 157:463–465 [B]
289. Tohen M., Sanger T.M., McElroy S.L., Tollefson G.D., Chengappa K.N.R., Daniel D.G., Petty F., Centorrino F., Wang R., Grundy S.L., Greaney M.G., Jacobs T.G., David S.R., Toma V. (Olanzapine HGEH Study Group): Olanzapine versus placebo in the treatment of acute mania. *Am. J. Psychiatry* 1999; 156:702–709 [A]
290. Tohen M., Jacobs T.G., Grundy S.L., McElroy S.L., Banov M.C., Janicak P.G., Sanger T., Risser R., Zhang F., Toma V., Francis J., Tollefson G.D., Breier A. (Olanzapine HGGW Study Group): Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. *Arch. Gen. Psychiatry* 2000; 57:841–849 [A]
291. Sanger T.M., Grundy S.L., Gibson P.J., Namjoshi M.A., Greaney M.G., Tohen M.F.: Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. *J. Clin. Psychiatry* 2001; 62:273–281 [E]
292. Tohen M., Zhang F., Feldman P.D., Evans A.R., Brier A.: Olanzapine versus haloperidol in the treatment of acute mania, in 1998 Annual Meeting Syllabus and Proceedings Summary. Washington, DC, American Psychiatric Association, 1998 [A]
293. Crawford A.M., Beasley C.M. Jr., Tollefson G.D.: The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. *Schizophr. Res.* 1997; 26:41–54 [A]
294. Kinon B.J., Basson B.R., Gilmore J.A., Tollefson G.D.: Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. *J. Clin. Psychiatry* 2001; 62:92–100 [A]

295. Allison D.B., Casey D.E.: Antipsychotic-induced weight gain: a review of the literature. *J. Clin. Psychiatry* 2001; 62 (suppl 7):22–31 [F]
296. Lindenmayer J.P., Nathan A.M., Smith R.C.: Hyperglycemia associated with the use of atypical antipsychotics. *J. Clin. Psychiatry* 2001; 62 (suppl 23):30–38 [F]
297. Leucht S., Pitschel-Walz G., Abraham D., Kissling W.: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. *Schizophr. Res.* 1999; 35:51–68 [E]
298. Beasley C.M., Dellva M.A., Tamura R.N., Morgenstern H., Glazer W.M., Ferguson K., Tollefson G.D.: Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. *Br. J. Psychiatry* 1999; 174:23–30 [A]
299. Chou J.C., Czobor P., Charles O., Tuma I., Winsberg B., Allen M.H., Trujillo M., Volavka J.: Acute mania: haloperidol dose and augmentation with lithium or lorazepam. *J. Clin. Psychopharmacol.* 1999; 19:500–505 [A]
300. Klein D.F.: Importance of psychiatric diagnosis in prediction of clinical drug effects. *Arch. Gen. Psychiatry* 1967; 16:118–126 [A]
301. Sachs G.S.: Emerging data: atypical antipsychotics in bipolar disorder, in Program and Abstracts of the 52nd Institute on Psychiatric Services. Washington, DC, APA, 2001 [A]
302. Keck P.E. Jr.: Atypical antipsychotics in the treatment of aggressive behaviors, in 2001 Annual Meeting Syllabus and Proceedings Summary. Washington, DC, American Psychiatric Association, 2001 [A]
303. Suppes T., Webb A., Paul B., Carmody T., Kraemer H., Rush A.J.: Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. *Am. J. Psychiatry* 1999; 156:1164–1169 [B]
304. Calabrese J.R., Kimmel S.E., Woyshville M.J., Rapport D.J., Faust C.J., Thompson P.A., Meltzer H.Y.: Clozapine for treatment-refractory mania. *Am. J. Psychiatry* 1996; 153: 759–764 [B]
305. Green A.I., Tohen M., Patel J.K., Banov M., DuRand C., Berman I., Chang H., Zarate C. Jr., Posener J., Lee H., Dawson R., Richards C., Cole J.O., Schatzberg A.F.: Clozapine in the treatment of refractory psychotic mania. *Am. J. Psychiatry* 2000; 157:982–986 [B]
306. Muller-Oerlinghausen B., Retzow A., Henn F.A., Giedke H., Walden J. (European Valproate Mania Study Group): Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multi-center study. *J. Clin. Psychopharmacol.* 2000; 20:195–203 [A]
307. Yatham L.N.: Safety and efficacy of risperidone as combination therapy for the manic phase of bipolar disorder: preliminary findings of a randomized double blind study (RIS-INT-46). *Int. J. Neuropsychopharmacol.* 2000; 3 (suppl 1):S142 [A]
308. Small J.G., Klapper M.H., Kellams J.J., Miller M.J., Milstein V., Sharpley P.H., Small I.F.: Electroconvulsive treatment compared with lithium in the management of manic states. *Arch. Gen. Psychiatry* 1988; 45:727–732 [A]
309. Mukherjee S., Sackeim H.A., Schnur D.B.: Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. *Am. J. Psychiatry* 1994; 151:169–176 [F]
310. Sikdar S., Kulhara P., Avasthi A., Singh H.: Combined chlorpromazine and electroconvulsive therapy in mania. *Br. J. Psychiatry* 1994; 164:806–810 [A]
311. Black D.W., Winokur G., Nasrallah A.: Treatment of mania: a naturalistic study of electroconvulsive therapy versus lithium in 438 patients. *J. Clin. Psychiatry* 1987; 48:132–139 [C]
312. Thomas J., Reddy B.: The treatment of mania: a retrospective evaluation of the effects of ECT, chlorpromazine, and lithium. *J. Affect. Disord.* 1982; 4:85–92 [D]
313. Ciapparelli A., Dell'Osso L., Tundo A., Pini S., Chiavacci M.C., Di Sacco I., Cassano G.B.: Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. *J. Clin. Psychiatry* 2001; 62:552–555 [B]

314. Devanand D.P., Polanco P., Cruz R., Shah S., Paykina N., Singh K., Majors L.: The efficacy of ECT in mixed affective states. *J. ECT* 2000; 16:32–37 [B]
315. Gruber N.P., Dilsaver S.C., Shoaib A.M., Swann A.C.: ECT in mixed affective states: a case series. *J. ECT* 2000; 16:183–188 [G]
316. McElroy S.L., Keck P.E. Jr.: Pharmacologic agents for the treatment of acute bipolar mania. *Biol. Psychiatry* 2000; 48:539–557 [F]
317. Lenox R.H., Newhouse P.A., Creelman W.L., Whitaker T.M.: Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. *J. Clin. Psychiatry* 1992; 53:47–52 [A]
318. Edwards R., Stephenson U., Flewett T.: Clonazepam in acute mania: a double blind trial. *Aust. NZ J. Psychiatry* 1991; 25:238–242 [A]
319. Chouinard G., Young S.N., Annable L.: Antimanic effect of clonazepam. *Biol. Psychiatry* 1983; 18:451–466 [B]
320. Chouinard G.: Clonazepam in acute and maintenance treatment of bipolar affective disorder. *J. Clin. Psychiatry* 1987; 48 (Oct suppl):29–37 [B]
321. Chouinard G., Annable L., Turnier L., Holobow N., Szkrumelak N.: A double-blind randomized clinical trial of rapid tranquilization with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms. *Can. J. Psychiatry* 1993; 38 (suppl 4):S114–S121 [A]
322. Meehan K., Zhang F., David S., Tohen M., Janicak P., Small J., Koch M., Rizk R., Walker D., Tran P., Breier A.: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. *J. Clin. Psychopharmacol.* 2001; 21:389–397 [A]
323. Walton S.A., Berk M., Brook S.: Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. *J. Clin. Psychiatry* 1996; 57:543–546 [A]
324. Janicak P.G., Sharma R.P., Pandey G., Davis J.M.: Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. *Am. J. Psychiatry* 1998; 155:972–973 [A]
325. Pazzaglia P.J., Post R.M., Ketter T.A., George M.S., Marangell L.B.: Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. *Psychiatry. Res.* 1993; 49:257–272 [A]
326. Zornberg G.L., Pope H.G. Jr.: Treatment of depression in bipolar disorder: new directions for research. *J. Clin. Psychopharmacol.* 1993; 13:397–408 [F]
327. Ballenger J.C., Post R.M.: Carbamazepine in manic-depressive illness: a new treatment. *Am. J. Psychiatry* 1980; 137:782–790 [B]
328. Dilsaver S.C., Swann S.C., Chen Y.W., Shoaib A., Joe B., Krajewski K.J., Gruber N., Tsai Y.: Treatment of bipolar depression with carbamazepine: results of an open study. *Biol. Psychiatry* 1996; 40:935–937 [G]
329. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. (Lamictal 602 Study Group): A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. *J. Clin. Psychiatry* 1999; 60: 79–88 [A]
330. Bowden C.L.: Novel treatments for bipolar disorder. *Expert Opin. Investig. Drugs* 2001; 10:661–671 [F]
331. Calabrese J.R., Bowden C.L., McElroy S.L., Cookson J., Andersen J., Keck P.E. Jr., Rhodes L., Bolden-Watson C., Zhou J., Ascher J.A.: Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. *Am. J. Psychiatry* 1999; 156:1019–1023 [B]
332. Deveaugh-Geiss J., Ascher J., Brook S., Cedrone J., Earl N., Emsley R., Frangou S., Huffman R.: Safety and tolerability of lamotrigine in controlled monotherapy. in American College of Neuropsychopharmacology Annual Meeting Poster Abstracts. Nashville, Tenn, ACNP, 2000 [G]
333. Sullivan J.R., Shear N.H.: The drug hypersensitivity syndrome: what is the pathogenesis? *Arch. Dermatol.* 2001; 137:357–364 [G]
334. Guberman A.H., Besag F.M., Brodie M.J., Dooley J.M., Duchowny M.S., Pellock J.M., Richens A., Stern R.S., Trevathan E.: Lamotrigine-associated rash: risk/benefit considerations in adults and children. *Epilepsia* 1999; 40:985–991 [G]

335. Messenheimer J., Mullens E.L., Giorgi L., Young F.: Safety review of adult clinical trial experience with lamotrigine. *Drug Saf.* 1998; 18:281–296 [F]
336. Fitton A., Goa K.L.: Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. *Drugs* 1995; 50:691–713 [F]
337. Rambeck B., Wolt P.: Lamotrigine clinical pharmacokinetics. *Clin. Pharmacokinet.* 1993; 25:433–443 [F]
338. McIntyre R.S., Mancini D., McCann J.M.: Randomized, single-blind comparison of topiramate and bupropion SR as add-on therapy in bipolar depression (abstract). *Acta Neuropsychiatrica* 2000; 12:163 [B]
339. Hussein M.Z.: Treatment of bipolar depression with topiramate (abstract). *Eur. Neuropsychopharmacol.* 1999; 9 (suppl 5):S222 [B]
340. Himmelhoch J.M., Thase M.E., Mallinger A.G., Houck P.: Tranylcypromine versus imipramine in anergic bipolar depression. *Am. J. Psychiatry* 1991; 148:910–916 [A]
341. Thase M.E., Mallinger A.G., McKnight D., Himmelhoch J.M.: Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. *Am. J. Psychiatry* 1992; 149:195–198 [A]
342. Baumhackl U., Biziere K., Fischbach R., Geretsegger C., Hebenstreit G., Radmayr E., Stabl M.: Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study. *Br. J. Psychiatry Suppl* 1989; 6: 78–83 [A]
343. Cohn J.B., Collins G., Ashbrook E., Wernicke J.F.: A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. *Int. Clin. Psychopharmacol.* 1989; 4:313–322 [A]
344. Young L.T., Joffe R.T., Robb J.C., MacQueen G.M., Marriott M., Patelis-Siotis I.: Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. *Am. J. Psychiatry* 2000; 157:124–126 [A]
345. Nemeroff C.B., Evans D.L., Gyulai L., Sachs G.S., Bowden C.L., Gergel I.P., Oakes R., Pitts C.D.: Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. *Am. J. Psychiatry* 2001; 158:906–912 [A]
346. Vieta E., Martinez-Aran A., Goikolea J.M.: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. *J. Clin. Psychiatry* (w druku) [A]
347. Kupfer D.J., Chengappa K.N., Gelenberg A.J., Hirschfeld R.M., Goldberg J.F., Sachs G.S., Grochocinski V.J., Houck P.R., Kolar K.B.: Citalopram as adjunctive therapy in bipolar depression. *J. Clin. Psychiatry* 2001; 62:985–990 [B]
348. Sachs G.S., Lafer B., Stoll A.L., Banov M., Thibault A.B., Tohen M., Rosenbaum J.F.: A double-blind trial of bupropion versus desipramine for bipolar depression. *J. Clin. Psychiatry* 1994; 55:391–393 [A]
349. Grossman F., Potter W.Z., Brown E.A., Maislin G.: A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. *J. Affect. Disord.* 1999; 56:237–243 [A]
350. Amsterdam J.D., Garcia-Espana F.: Venlafaxine monotherapy in women with bipolar II and unipolar major depression. *J. Affect. Disord.* 2000; 59:225–229 [A]
351. Wehr T.A., Sack D.A., Rosenthal N.E.: Sleep reduction as a final common pathway in the genesis of mania. *Am. J. Psychiatry* 1987; 144:201–204; correction, 144:542 [F]
352. Smeraldi E., Benedetti F., Barbini B., Campori E., Colombo C.: Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression: a placebo-controlled trial. *Neuropsychopharmacology* 1999; 20:380–385 [A]
353. Colombo C., Lucca A., Benedetti F., Barbini B., Campori E., Smeraldi E.: Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. *Psychiatry Res.* 2000; 95:43–53 [A]

354. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., Cress K.K., Marangell L.B.: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. *Arch. Gen. Psychiatry* 1999; 56:407–412 [A]
355. Sporn J., Ghaemi S.N., Sambur M.R., Rankin M.A., Recht J., Sachs G.S., Rosenbaum J.F., Fava M.: Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. *Ann. Clin. Psychiatry* 2000; 12:137–140 [D]
356. George M.S., Sackeim H.A., Rush A.J., Marangell L.B., Nahas Z., Husain M.M., Lisanby S., Burt T., Goldman J., Ballenger J.C.: Vagus nerve stimulation: a new tool for brain research and therapy. *Biol. Psychiatry* 2000; 47:287–295 [F]
357. Nahas Z., Molloy M.A., Hughes P.L., Oliver N.C., Arana G.W., Risch S.C., George M.S.: Repetitive transcranial magnetic stimulation: perspectives for application in the treatment of bipolar and unipolar disorders. *Bipolar Disord.* 1999; 1:73–80 [F]
358. Cole A.J., Scott J., Ferrier I.N., Eccleston D.: Patterns of treatment resistance in bipolar affective disorder. *Acta Psychiatr. Scand.* 1993; 88:121–123 [C]
359. Dunner D.L., Fieve R.R.: Clinical factors in lithium carbonate prophylaxis failure. *Arch. Gen. Psychiatry* 1974; 30:229–233 [F]
360. Peet M.: Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. *Br. J. Psychiatry* 1994; 164:549–550 [E]
361. Okuma T., Inanaga K., Otsuki S., Sarai K., Takahashi R., Hazama H., Mori A., Watanabe S.: A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. *Psychopharmacology (Berl)* 1981; 73:95–96 [A]
362. Denicoff K.D., Smith-Jackson E.E., Disney E.R., Ali S.O., Leverich G.S., Post R.M.: Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. *J. Clin. Psychiatry* 1997; 58:470–478 [B]
363. Bauer M.S., Whybrow P.C., Gyulai L., Gonnell J., Yeh H.S.: Testing definitions of dysphoric mania and hypomania: prevalence, clinical characteristics and inter-episode stability. *J. Affect. Disord.* 1994; 32:201–211 [C]
364. Maj M., Pirozzi R., Magliano L., Bartoli L.: Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. *Am. J. Psychiatry* 1998; 155:30–35 [C]
365. Dunner D.L., Stallone F., Fieve R.R.: Lithium carbonate and affective disorders, V: a double-blind study of prophylaxis of depression in bipolar illness. *Arch. Gen. Psychiatry* 1976; 33:117–120 [A]
366. Shapiro D.R., Quitkin F.M., Fleiss J.L.: Response to maintenance therapy in bipolar illness: effect of index episode. *Arch. Gen. Psychiatry* 1989; 46:401–405 [E]
367. Bowden C.L., Calabrese J.R., McElroy S.L., Rhodes L.J., Keck P.E. Jr., Cookson J., Anderson J., Bolden-Watson C., Ascher J., Monaghan E., Zhou J.: The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. *Biol. Psychiatry* 1999; 45: 953–958 [G]
368. Calabrese J.R., Delucchi G.A.: Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. *Am. J. Psychiatry* 1990; 147:431–434 [G]
369. Calabrese J.R., Woyshville M.J., Kimmel S.E., Rapport D.J.: Predictors of valproate response in bipolar rapid cycling. *J. Clin. Psychopharmacol.* 1993; 13:280–283 [E]
370. Sachs G.S., Printz D.J., Kahn D.A., Carpenter D., Docherty J.P.: The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder. *Postgrad. Med. Special Issue* 2000; 1:1–104 [G]
371. Bowden C.L., Lecrubier Y., Bauer M., Goodwin G., Greil W., Sachs G., von Knorring L.: Maintenance therapies for classic and other forms of bipolar disorder. *J. Affect. Disord.* 2000; 59 (suppl 1): S57–S67 [F]
372. Baldessarini R.J., Tohen M., Tondo L.: Maintenance treatment in bipolar disorder. *Arch. Gen. Psychiatry* 2000; 57:490–492 [G]

373. Baastrup P.C., Poulsen J.C., Schou M., Thomsen K., Amdisen A.: Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. *Lancet* 1970; 2:326–330 [A]
374. Melia P.I.: Prophylactic lithium: a double-blind trial in recurrent affective disorders. *Br. J. Psychiatry* 1970; 116:621–624 [A]
375. Coppen A., Peet M., Bailey J., Noguera R., Burns B.H., Swani M.S., Maggs R., Gardner R.: Double-blind and open prospective studies on lithium prophylaxis in affective disorders. *Psychiatr. Neurol. Neurochir.* 1973; 76:501–510 [F]
376. Cundall R.L., Brooks P.W., Murray L.G.: A controlled evaluation of lithium prophylaxis in affective disorders. *Psychol. Med.* 1972; 2:308–311 [B]
377. Prien R.F., Caffey E.M. Jr., Klett C.J.: Prophylactic efficacy of lithium carbonate in manic-depressive illness: report of the Veterans Administration and National Institute of Mental Health collaborative study group. *Arch. Gen. Psychiatry* 1973; 28:337–341 [A]
378. Suppes T., Baldessarini R.J., Faedda G.L., Tohen M.: Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. *Arch. Gen. Psychiatry* 1991; 48:1082–1088 [E]
379. Markar H.R., Mander A.J.: Efficacy of lithium prophylaxis in clinical practice. *Br. J. Psychiatry* 1989; 155:496–500 [F]
380. Harrow M., Goldberg J.F., Grossman L.S., Meltzer H.Y.: Outcome in manic disorders: a naturalistic follow-up study. *Arch. Gen. Psychiatry* 1990; 47:665–671 [C]
381. Coryell W., Winokur G., Solomon D., Shea T., Leon A., Keller M.: Lithium and recurrence in a long-term follow-up of bipolar affective disorder. *Psychol. Med.* 1997; 27:281–289 [C]
382. Gitlin M.J., Swendsen J., Heller T.L., Hammen C.: Relapse and impairment in bipolar disorder. *Am. J. Psychiatry* 1995; 152:1635–1640 [C]
383. Licht R.W., Vestergaard P., Rasmussen N.A., Jepsen K., Brodersen A., Hansen P.E.: A lithium clinic for bipolar patients: 2-year outcome of the first 148 patients. *Acta Psychiatr. Scand.* 2001; 104: 387–390 [B]
384. Peselow E.D., Fieve R.R., Difiglia C., Sanfilipo M.P.: Lithium prophylaxis of bipolar illness: the value of combination treatment. *Br. J. Psychiatry* 1994; 164:208–214 [D]
385. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., Pope H.G. Jr., Chou J.C., Keck P.E. Jr., Rhodes L.J., Swann A.C., Hirschfeld R.M., Wozniak P.J. (Divalproex Maintenance Study Group): A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. *Arch. Gen. Psychiatry* 2000; 57:481–489 [A]
386. Calabrese J.R., Bowden C.L., DeVeaugh-Geiss J., Earl N.L., Gyulai L., Sachs G.S., Montgomery P.: Lamotrigine demonstrates long-term mood stabilization in manic patients, in 2001 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 2001, 110 [A]
387. Greil W., Ludwig-Mayerhofer W., Erazo N., Schochlin C., Schmidt S., Engel R.R., Czernik A., Giedke H., Muller-Oerlinghausen B., Osterheider M., Rudolf G.A., Sauer H., Tegeler J., Wetterling T.: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders – a randomised study. *J. Affect. Disord.*, 1997; 43:151–161 [B]
388. Lambert P.A., Venaud G.: [Comparative study of valpromide versus lithium as prophylactic treatment: in affective disorders.] *Nervure* 1992; 5:57–65 (French) [B]
389. Greil W., Kleindienst N., Erazo N., Muller-Oerlinghausen B.: Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. *J. Clin. Psychopharmacol.* 1998; 18: 455–460 [E]
390. Stromgren L.S.: The combination of lithium and carbamazepine in treatment and prevention of manic-depressive disorder: a review and a case report. *Compr. Psychiatry* 1990; 31: 261–265 [E]
391. Esparon J., Kolloori J., Naylor G.J., McHarg A.M., Smith A.H., Hopwood S.E.: Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. *Br. J. Psychiatry* 1986; 148:723–725 [A]

392. Stevenson G.H., Geoghegan J.J.: Prophylactic electroshock; a five-year study. *Am. J. Psychiatry* 1951; 107:743–748 [B]
393. Geoghegan J.J., Stevenson G.H.: Prophylactic electroshock. *Am. J. Psychiatry* 1949; 105: 494–496 [B]
394. Godemann F., Hellweg R.: [20 years unsuccessful prevention of bipolar affective psychosis recurrence.] *Nervenarzt* 1997; 68: 582–585 (German) [F]
395. Chanpattana W.: Combined ECT and clozapine in treatment-resistant mania. *J. ECT* 2000; 16:204–207 [G]
396. Decina P., Schlegel A.M., Fieve R.R.: Lithium poisoning. *NY State J. Med.* 1987; 87: 230–231 [G]
397. Kramer B.A.: A naturalistic review of maintenance ECT at a university setting. *J. ECT* 1999; 15:262–269 [G]
398. Rhodes L.J.: Maintenance ECT replaced with lamotrigine (letter). *Am. J. Psychiatry* 2000; 157:2058 [G]
399. Gupta S., Austin R., Devanand D.P.: Lithium and maintenance electroconvulsive therapy. *J. ECT* 1998; 14:241–244 [G]
400. Barnes R.C., Hussein A., Anderson D.N., Powell D.: Maintenance electroconvulsive therapy and cognitive function. *Br. J. Psychiatry* 1997; 170:285–287 [G]
401. Jaffe R., Dubin W.R.: Oral versus intravenous caffeine augmentation of ECT (letter). *Am. J. Psychiatry* 1992; 149:1610 [G]
402. Karliner W.: Accidental convulsion induced by atropine. *Am. J. Psychiatry* 1965; 122: 578–579 [G]
403. Clarke L.: Psychiatric nursing and electroconvulsive therapy. *Nurs. Ethics* 1995; 2:321–331 [F]
404. Kramer B.A.: A seasonal schedule for maintenance ECT. *J. ECT* 1999; 15:226–231 [G]
405. Vanelle J.M., Loo H., Galinowski A., de Carvalho W., Bourdel M.C., Brochier P., Bouvet O., Brochier T., Olie J.P.: Maintenance ECT in intractable manic-depressive disorders. *Convuls. Ther.* 1994; 10:195–205[B]
406. Schwarz T., Loewenstein J., Isenberg K.E.: Maintenance ECT: indications and outcome. *Convuls. Ther.* 1995; 11:14–23 [B]
407. Gagne G.G. Jr., Furman M.J., Carpenter L.L., Price L.H.: Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. *Am. J. Psychiatry* 2000; 157:1960–1965 [B]
408. Kahn D.A.: The use of psychodynamic psychotherapy in manic-depressive illness. *J. Am. Acad. Psychoanal.* 1993; 21:441–455 [A]
409. Haas G.L., Glick I.D., Clarkin J.F., Spencer J.H., Lewis A.B., Peyser J., DeMane N., Good-Ellis M., Harris E., Lestelle V.: Inpatient family intervention: a randomized clinical trial, II: results at hospital discharge. *Arch. Gen. Psychiatry* 1988; 45:217–224 [A]
410. Clarkin J.F., Carpenter D., Hull J., Wilner P., Glick I.: Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses. *Psychiatr. Serv.* 1998; 49:531–533 [A]
411. Miklowitz D.J., Goldstein M.J.: *Bipolar Disorder: A Family-Focused Treatment Approach*. New York, Guilford Press, 1997 [G]
412. Miklowitz D.J., Simoneau T.L., George E.L., Richards J.A., Kalbag A., Sachs-Ericsson N., Suddath R.: Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. *Biol. Psychiatry* 2000; 48:582–592 [A]
413. Basco M.R., Rush A.J.: *Cognitive-Behavioral Therapy for Bipolar Disorder*. New York, Guilford Press, 1996 [G]
414. Zaretsky A.E., Segal Z.V., Gemar M.: Cognitive therapy for bipolar depression: a pilot study. *Can. J. Psychiatry* 1999; 44:491–494 [B]
415. Fava G.A., Bartolucci G., Rafanelli C., Mangelli L.: Cognitive-behavioral management of patients with bipolar disorder who relapsed while on lithium prophylaxis. *J. Clin. Psychiatry* 2001; 62:556–559 [B]

416. Cochran S.D.: Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. *J. Consult. Clin. Psychol.* 1984; 52:873–878 [A]
417. Ehlers C.L., Frank E., Kupfer D.J.: Social zeitgebers and biological rhythms: a unified approach to understanding the etiology of depression. *Arch. Gen. Psychiatry* 1988; 45:948–952 [F]
418. Frank E., Hlastala S., Ritenour A., Houck P., Tu X.M., Monk T.H., Mallinger A.G., Kupfer D.J.: Inducing lifestyle regularity in recovering bipolar disorder patients: results from the maintenance therapies in bipolar disorder protocol. *Biol. Psychiatry* 1997; 41:1165–1173 [A]
419. Frank E., Swartz H.A., Kupfer D.J.: Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. *Biol. Psychiatry* 2000; 48:593–604 [F]
420. Cole D.P., Thase M.E., Mallinger A.G., Soares J.C., Luther J.F., Kupfer D.J., Frank E.: Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. *Am. J. Psychiatry* 2002; 159:116–121 [A]
421. Frank E., Swartz H.A., Mallinger A.G., Thase M.E., Weaver E.V., Kupfer D.J.: Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. *J. Abnorm. Psychol.* 1999; 108: 579–587 [A]
422. Colom F., Vieta E., Benabarre A., Martinez-Aran A., Reinares M., Corbella B., Gasto C.: Topiramate abuse in a bipolar patient with an eating disorder. *J. Clin. Psychiatry* 2001; 62: 475–476 [G]
423. Beck A.T., Rush A.J., Shaw B.F., Emery G.: *Cognitive Therapy of Depression*. New York, Guilford, 1979 [G]
424. Klerman G.L., Weissman M.M., Rounsaville B.J., Chevron E.S.: *Interpersonal Psychotherapy of Depression*. New York, Basic Books, 1984 [G]
425. Frank E., Kupfer D.J., Perel J.M., Cornes C., Jarrett D.B., Mallinger A.G., Thase M.E., McEachran A.B., Grochocinski V.J.: Three-year outcomes for maintenance therapies in recurrent depression. *Arch. Gen. Psychiatry* 1990; 47:1093–1099 [A]
426. Weissman M.M., Markowitz J.C., Klerman G.L.: *Comprehensive Guide to Interpersonal Psychotherapy*. New York, Basic Books, 2000 [G]
427. Frank E., Kupfer D.J., Gibbons R., Houck P., Kostelnik B., Mallinger A.G., Swartz H.A., Thase M.E.: Interpersonal and social rhythm therapy prevents depressive symptomatology in patients with bipolar I disorder. *Arch. Gen. Psychiatry* (in press) [A]
428. Bauer M.S., McBride L., Chase C., Sachs G., Shea N.: Manual-based group psychotherapy for bipolar disorder: a feasibility study. *J. Clin. Psychiatry* 1998; 59:449–455 [B]
429. Rush A.J., Thase M.E.: Psychotherapies for depressive disorders: a review, in *Evidence and Experience in Psychiatry*, vol 1: Depressive Disorders. Edited by Maj M., Sartorius N. Chichester U.K. John Wiley & Sons. 1999, 161–206 [G]
430. Blacker D., Tsuang M.T.: Contested boundaries of bipolar disorder and the limits of categorical diagnosis in psychiatry. *Am. J. Psychiatry* 1992; 149:1473–1483 [F]
431. Akiskal H.S., Hirschfeld R.M., Yerevanian B.I.: The relationship of personality to affective disorders. *Arch. Gen. Psychiatry* 1983; 40:801–810 [F]
432. Geller B., Cooper T.B., Sun K., Zimmerman B., Frazier J., Williams M., Heath J.: Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. *J. Am. Acad. Child. Adolesc. Psychiatry* 1998; 37:171–178 [A]
433. Gram L.F., Rafaelsen O.J.: Lithium treatment of psychotic children and adolescents: a controlled clinical trial. *Acta Psychiatr. Scand.* 1972; 48:253–260 [A]
434. Lena B.: Lithium in child and adolescent psychiatry. *Arch. Gen. Psychiatry* 1979; 36: 854–855 [A]
435. McKnew D.H., Cytryn L., Buchsbaum M.S., Hamovit J., Lamour M., Rapoport J.L., Gershon E.S.: Lithium in children of lithium-responding parents. *Psychiatry Res.* 1981; 4:171–180 [A]
436. DeLong G.R., Nieman G.W.: Lithium-induced behavior changes in children with symptoms suggesting manic-depressive illness. *Psychopharmacol. Bull.* 1983; 19:258–265 [A]
437. Ansell A.L.: Manic-depressive illness in children and effect of treatment with lithium carbonate. *Acta Paedopsychiatr.* 1969; 36:292–301 [G]

438. Dyson W.L., Barcai A.: Treatment of children of lithium-responding parents. *Curr. Ther. Res. Clin. Exp.* 1970; 12:286–290 [G]
439. Dugas M., Gueriot C., Frohworth C.: [Has lithium a value in child psychiatry.] *Rev. Neuropsychiatr. Infant.* 1975; 23:365–372 (French) [B]
440. Watanabe S., Ishino H., Otsuki S.: Double-blind comparison of lithium carbonate and imipramine in treatment of depression. *Arch. Gen. Psychiatry* 1975; 32:659–668 [A]
441. Brumback R.A., Weinberg W.A.: Mania in childhood, II: therapeutic trial of lithium carbonate and further description of manic-depressive illness in children. *Am. J. Dis. Child.* 1977; 131:1122–1126 [B]
442. Horowitz H.A.: Lithium and the treatment of adolescent manic depressive illness. *Dis. Nerv. Syst.* 1977; 38:480–483 [G]
443. Carlson G.A., Strober M.: Manic-depressive illness in early adolescence: a study of clinical and diagnostic characteristics in six cases. *J. Am. Acad. Child Psychiatry* 1978; 17:138–153 [C]
444. Davis R.E.: Manic-depressive variant syndrome of childhood: a preliminary report. *Am. J. Psychiatry* 1979; 136:702–706 [G]
445. Hassanyeh F., Davison K.: Bipolar affective psychosis with onset before age 16 years: report of 10 cases. *Br. J. Psychiatry* 1980; 137:530–539 [G]
446. Rogeness G.A., Riester A.E., Wicoff J.S.: Unusual presentation of manic depressive disorder in adolescence. *J. Clin. Psychiatry* 1982; 43:37–39 [G]
447. Sylvester C.E., Burke P.M., McCauley E.A., Clark C.J.: Manic psychosis in childhood: report of two cases. *J. Nerv. Ment. Dis.* 1984; 172: 12–15 [G]
448. DeLong G.R., Aldershof A.L.: Long-term experience with lithium treatment in childhood: correlation with clinical diagnosis. *J. Am. Acad. Child. Adolesc. Psychiatry* 1987; 26:389–394 [B]
449. Hsu L.K., Starzynski J.M.: Mania in adolescence. *J. Clin. Psychiatry.* 1986; 47:596–599 [C]
450. Hsu L.K.: Lithium-resistant adolescent mania. *J. Am. Acad. Child. Psychiatry.* 1986; 25: 280–283 [G]
451. Varanka T.M., Weller R.A., Weller E.B., Fristad M.A.: Lithium treatment of manic episodes with psychotic features in prepubertal children. *Am. J. Psychiatry* 1988; 145:1557–1559 [B]
452. Tomasson K., Kuperman S.: Bipolar disorder in a prepubescent child. *J. Am. Acad. Child Adolesc. Psychiatry* 1990; 29:308–310 [F]
453. Carlson G.A., Rapport M.D., Pataki C.S., Kelly K.L.: Lithium in hospitalized children at 4 and 8 weeks: mood, behavior and cognitive effects. *J. Child Psychol. Psychiatry* 1992; 33:411–425 [A]
454. Kafantaris V., Coletti D.J., Dicker R., Padula G., Pollack S.: Are childhood psychiatric histories of bipolar adolescents associated with family history, psychosis, and response to lithium treatment? *J. Affect. Disord.* 1998; 51:153–164 [A]
455. Strober M., DeAntonio M., Schmidt-Lackner S., Freeman R., Lampert C., Diamond J.: Early childhood attention deficit hyperactivity disorder predicts poorer response to acute lithium therapy in adolescent mania. *J. Affect. Disord.* 1998; 51:145–151 [B]
456. Papatheodorou G., Kutcher S.P.: Divalproex sodium treatment in late adolescent and young adult acute mania. *Psychopharmacol. Bull.* 1993; 29:213–219 [B]
457. Papatheodorou G., Kutcher S.P., Katic M., Szalai J.P.: The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial. *J. Clin. Psychopharmacol.* 1995; 15:110–116 [B]
458. Wagner K.D.: Safety and efficacy of divalproex in childhood bipolar disorder, in *Abstracts of Posters Presented at the 2000 Annual Meeting of the American Academy of Child and Adolescent Psychiatry*. Washington, DC, AACAP, 2000 [G]
459. Kastner T., Friedman D.L.: Verapamil and valproic acid treatment of prolonged mania. *J. Am. Acad. Child. Adolesc. Psychiatry* 1992; 31:271–275 [D]
460. Kastner T., Friedman D.L., Plummer A.T., Ruiz M.Q., Henning D.: Valproic acid for the treatment of children with mental retardation and mood symptomatology. *Pediatrics* 1990; 86: 467–472 [G]

461. Whittier M.C., West S.A., Galli V.B., Raute N.J.: Valproic acid for dysphoric mania in a mentally retarded adolescent. *J. Clin. Psychiatry* 1995; 56:590–591 [G]
462. Deltito J.A., Levitan J., Damore J., Hajal F., Zambenedetti M.: Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescent psychiatric patients. *Acta Psychiatr. Scand.* 1998; 97:236–240 [E]
463. Kowatch R.A., Suppes T., Carmody T.J., Bucci J.P., Hume J.H., Kromelis M., Emslie G.J., Weinberg W.A., Rush A.J.: Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. *J. Am. Acad. Child Adolesc. Psychiatry* 2000; 39:713–720 [A]
464. Woolston J.L.: Case study: carbamazepine treatment of juvenile-onset bipolar disorder. *J. Am. Acad. Child Adolesc. Psychiatry* 1999; 38:335–338 [G]
465. Frazier J.A., Biederman J., Jacobs T.G., Tohen M.F., Toma V., Feldman P.D., Rater M.A., Tarazi R.A., Kim G.A., Garfield S.B., Gonzalez-Heydrich J., Nowlin Z.M.: Olanzapine in the treatment of bipolar disorder in juveniles, in New Clinical Drug Evaluation Unit 2000 Program Abstracts. Washington, DC, NCDEU, 2000, poster 46 [G]
466. Chang K.D., Ketter T.A.: Mood stabilizer augmentation with olanzapine in acutely manic children. *J. Child Adolesc. Psychopharmacol.* 2000; 10:45–49 [G]
467. Soutullo C.A., Sorter M.T., Foster K.D., McElroy S.L., Keck P.E.: Olanzapine in the treatment of adolescent acute mania: a report of seven cases. *J. Affect. Disord.* 1999; 53:279–283 [E]
468. Frazier J.A., Meyer M.C., Biederman J., Wozniak J., Wilens T.E., Spencer T.J., Kim G.S., Shapiro S.: Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. *J. Am. Acad. Child Adolesc. Psychiatry* 1999; 38:960–965 [F]
469. Ryback R.S., Brodsky L., Munasifi F.: Gabapentin in bipolar disorder (letter). *J. Neuropsychiatry Clin. Neurosci.* 1997; 9:301 [G]
470. Soutullo C.A., Casuto L.S., Keck P.E. Jr.: Gabapentin in the treatment of adolescent mania: a case report. *J. Child Adolesc. Psychopharmacol.* 1998; 8:81–85 [G]
471. Hill M.A., Courvoisie H., Dawkins K., Nofal P., Thomas B.: ECT for the treatment of intractable mania in two prepubertal male children. *Convuls. Ther.* 1997; 13:74–82 [G]
472. Rey J.M., Walter G.: Half a century of ECT use in young people. *Am. J. Psychiatry* 1997; 154:595–602 [F]